BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33420948)

  • 1. Insulin-like growth factor 2 (IGF2) expression in adrenocortical disease due to PRKAR1A mutations compared to other benign adrenal tumors.
    Nadella KS; Berthon A; Almeida MQ; Levy I; Faucz FR; Stratakis CA
    Endocrine; 2021 Jun; 72(3):823-834. PubMed ID: 33420948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase A subunit expression is altered in Bloom syndrome fibroblasts and the BLM protein is increased in adrenocortical hyperplasias: inverse findings for BLM and PRKAR1A.
    Heyerdahl SL; Boikos S; Horvath A; Giatzakis C; Bossis I; Stratakis CA
    Horm Metab Res; 2008 Jun; 40(6):391-7. PubMed ID: 18401830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A.
    Shi Z; Henwood MJ; Bannerman P; Batista D; Horvath A; Guttenberg M; Stratakis CA; Grimberg A
    Growth Horm IGF Res; 2007 Apr; 17(2):113-21. PubMed ID: 17280861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity.
    Bertherat J; Groussin L; Sandrini F; Matyakhina L; Bei T; Stergiopoulos S; Papageorgiou T; Bourdeau I; Kirschner LS; Vincent-Dejean C; Perlemoine K; Gicquel C; Bertagna X; Stratakis CA
    Cancer Res; 2003 Sep; 63(17):5308-19. PubMed ID: 14500362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of somatic beta-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD).
    Tadjine M; Lampron A; Ouadi L; Horvath A; Stratakis CA; Bourdeau I
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):367-73. PubMed ID: 18419788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRKAR1A mutations in primary pigmented nodular adrenocortical disease.
    Cazabat L; Ragazzon B; Groussin L; Bertherat J
    Pituitary; 2006; 9(3):211-9. PubMed ID: 17036196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer.
    Anselmo J; Medeiros S; Carneiro V; Greene E; Levy I; Nesterova M; Lyssikatos C; Horvath A; Carney JA; Stratakis CA
    J Clin Endocrinol Metab; 2012 Feb; 97(2):351-9. PubMed ID: 22112814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-KIT oncogene expression in PRKAR1A-mutant adrenal cortex.
    Nadella K; Faucz FR; Stratakis CA
    Endocr Relat Cancer; 2020 Oct; 27(10):591-599. PubMed ID: 32738126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of cyclic AMP signaling leads to different pathway alterations in lesions of the adrenal cortex caused by germline PRKAR1A defects versus those due to somatic GNAS mutations.
    Almeida MQ; Azevedo MF; Xekouki P; Bimpaki EI; Horvath A; Collins MT; Karaviti LP; Jeha GS; Bhattacharyya N; Cheadle C; Watkins T; Bourdeau I; Nesterova M; Stratakis CA
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E687-93. PubMed ID: 22259056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol Biosynthesis and Trafficking in Cortisol-Producing Lesions of the Adrenal Cortex.
    London E; Wassif CA; Horvath A; Tatsi C; Angelousi A; Karageorgiadis AS; Porter FD; Stratakis CA
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3660-7. PubMed ID: 26204136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation.
    Horvath A; Mathyakina L; Vong Q; Baxendale V; Pang AL; Chan WY; Stratakis CA
    J Clin Endocrinol Metab; 2006 Feb; 91(2):584-96. PubMed ID: 16278264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of PRKAR1A and Gs(alpha) in sporadic adrenocortical tumors.
    Libé R; Mantovani G; Bondioni S; Lania AG; Pedroni C; Beck-Peccoz P; Spada A
    Exp Clin Endocrinol Diabetes; 2005 May; 113(5):248-51. PubMed ID: 15926108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II.
    Kim SJ; Park SE; Lee C; Lee SY; Jo JH; Kim JM; Oh YK
    Biochim Biophys Acta; 2002 Apr; 1586(3):307-15. PubMed ID: 11997082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease.
    Groussin L; Jullian E; Perlemoine K; Louvel A; Leheup B; Luton JP; Bertagna X; Bertherat J
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4324-9. PubMed ID: 12213893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome.
    Hofland J; de Herder WW; Derks L; Hofland LJ; van Koetsveld PM; de Krijger RR; van Nederveen FH; Horvath A; Stratakis CA; de Jong FH; Feelders RA
    Eur J Endocrinol; 2013 Jan; 168(1):67-74. PubMed ID: 23065993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions.
    Griffin KJ; Kirschner LS; Matyakhina L; Stergiopoulos SG; Robinson-White A; Lenherr SM; Weinberg FD; Claflin ES; Batista D; Bourdeau I; Voutetakis A; Sandrini F; Meoli EM; Bauer AJ; Cho-Chung YS; Bornstein SR; Carney JA; Stratakis CA
    J Med Genet; 2004 Dec; 41(12):923-31. PubMed ID: 15591278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site.
    Ulaner GA; Vu TH; Li T; Hu JF; Yao XM; Yang Y; Gorlick R; Meyers P; Healey J; Ladanyi M; Hoffman AR
    Hum Mol Genet; 2003 Mar; 12(5):535-49. PubMed ID: 12588801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor.
    Bourdeau I; Lacroix A; Schürch W; Caron P; Antakly T; Stratakis CA
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3931-7. PubMed ID: 12915689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.
    Boikos SA; Horvath A; Heyerdahl S; Stein E; Robinson-White A; Bossis I; Bertherat J; Carney JA; Stratakis CA
    Horm Metab Res; 2008 May; 40(5):347-53. PubMed ID: 18491255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD.
    Groussin L; Kirschner LS; Vincent-Dejean C; Perlemoine K; Jullian E; Delemer B; Zacharieva S; Pignatelli D; Carney JA; Luton JP; Bertagna X; Stratakis CA; Bertherat J
    Am J Hum Genet; 2002 Dec; 71(6):1433-42. PubMed ID: 12424709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.